Kingsview Wealth Management LLC Grows Stake in Aflac Incorporated (NYSE:AFL)

Kingsview Wealth Management LLC raised its stake in Aflac Incorporated (NYSE:AFL - Free Report) by 18.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 39,243 shares of the financial services provider's stock after purchasing an additional 6,225 shares during the quarter. Kingsview Wealth Management LLC's holdings in Aflac were worth $4,363,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Golden State Wealth Management LLC lifted its holdings in shares of Aflac by 121.9% in the 1st quarter. Golden State Wealth Management LLC now owns 304 shares of the financial services provider's stock valued at $34,000 after buying an additional 167 shares during the period. Dynamic Advisor Solutions LLC acquired a new stake in shares of Aflac in the 1st quarter valued at approximately $206,000. GAMMA Investing LLC lifted its holdings in shares of Aflac by 11.6% in the 1st quarter. GAMMA Investing LLC now owns 13,527 shares of the financial services provider's stock valued at $1,504,000 after buying an additional 1,411 shares during the period. Garde Capital Inc. acquired a new stake in shares of Aflac in the 1st quarter valued at approximately $36,000. Finally, Hirtle Callaghan & Co LLC acquired a new stake in shares of Aflac in the 4th quarter valued at approximately $276,000. 67.44% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AFL. Keefe, Bruyette & Woods raised their price target on Aflac from $104.00 to $106.00 and gave the stock a "market perform" rating in a research report on Wednesday, May 7th. Piper Sandler raised their price target on Aflac from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 2nd. JPMorgan Chase & Co. raised their price target on Aflac from $96.00 to $100.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 8th. Barclays set a $98.00 price target on Aflac and gave the stock an "underweight" rating in a research report on Monday, July 7th. Finally, Morgan Stanley lifted their price objective on Aflac from $100.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, May 19th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $107.07.

Insider Activity

In other Aflac news, Director Joseph L. Moskowitz sold 1,000 shares of the stock in a transaction dated Thursday, May 8th. The shares were sold at an average price of $106.79, for a total value of $106,790.00. Following the transaction, the director directly owned 26,096 shares of the company's stock, valued at $2,786,791.84. This represents a 3.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arthur Reginald Collins sold 2,750 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $105.70, for a total transaction of $290,675.00. Following the transaction, the director owned 6,728 shares in the company, valued at approximately $711,149.60. The trade was a 29.01% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,750 shares of company stock valued at $4,304,295. 0.90% of the stock is owned by company insiders.

Aflac Price Performance

Shares of Aflac stock traded up $0.36 during midday trading on Friday, reaching $101.78. The company had a trading volume of 4,577,769 shares, compared to its average volume of 2,153,065. The company has a current ratio of 0.09, a quick ratio of 0.09 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $55.03 billion, a price-to-earnings ratio of 15.90, a price-to-earnings-growth ratio of 3.15 and a beta of 0.81. The stock has a fifty day simple moving average of $103.33 and a 200 day simple moving average of $105.17. Aflac Incorporated has a 1-year low of $93.00 and a 1-year high of $115.50.

Aflac (NYSE:AFL - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The financial services provider reported $1.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.67 by ($0.01). Aflac had a net margin of 21.27% and a return on equity of 15.55%. The firm had revenue of $3.40 billion during the quarter, compared to analyst estimates of $4.53 billion. During the same period last year, the firm earned $1.66 EPS. Aflac's quarterly revenue was down 37.5% on a year-over-year basis. As a group, equities research analysts forecast that Aflac Incorporated will post 6.88 earnings per share for the current year.

Aflac Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Wednesday, May 21st were given a dividend of $0.58 per share. The ex-dividend date of this dividend was Wednesday, May 21st. This represents a $2.32 annualized dividend and a yield of 2.28%. Aflac's dividend payout ratio (DPR) is presently 36.25%.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.